Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results tomorrow morning. Here’s what to expect. Omnicell beat analysts’ revenue expectations by 2.2% last quarter, reporting revenues of $306.9 million, up 18.6% year on year. It was a slower quarter for the company, with EBITDA guidance for next quarter missing analysts’ expectations. Is Omnicell a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Omnicell’s revenue to grow 5.6% year on year to $260 million, a reversal from the 15.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.20 per share.Omnicell Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Omnicell has missed Wall Street’s revenue estimates twice over the last two years. Looking at Omnicell’s peers in the healthcare technology segment, only Tandem Diabetes has reported results so far. It beat analysts’ revenue estimates by 6.8%, delivering year-on-year sales growth of 22.3%. The stock traded up 18.8% on the results. Read our full analysis of Tandem Diabetes’s earnings results here. There has been positive sentiment among investors in the healthcare technology segment, with share prices up 4.9% on average over the last month. Omnicell is up 1.2% during the same time and is heading into earnings with an average analyst price target of $50.71 (compared to the current share price of $31.99). Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Omnicell (OMCL) Q1 Earnings Report Preview: What To Look For
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...